EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Estimating the economic burden of colorectal cancer in China, 2019–2030: A population‐level prevalence‐based analysis

Hong Wang iD, Yan-Jie Li, Lin Lei iD, Cheng-Cheng Liu, Wan-Qing Chen iD, Min Dai iD, Xin Wang, Jie-Bin Lew iD, Ju-Fang Shi iD, Ni Li iD, Jie He

Cancer Medicine · 2024

DOI: 10.1002/cam4.6787 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Hong Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences …. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Cost of Illness, Health Expenditures. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: A Talent Incentive Plan Sponsored by Cancer Hospital, Chinese Academy of Medical Sciences, An Open Competition Grant from Health Policy and System Sciences of China Medical Board, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Colorectal cancer (CRC) is one of the most common cancers worldwide. Comprehensive data on the economic burden of CRC at a population‐level is critical in informing policymaking, but such data are currently limited in China.

Methods

From a societal perspective, the economic burden of CRC in 2019 was estimated, including direct medical and nonmedical expenditure, disability, and premature‐death‐related indirect expenditure. Data on disease burden was taken from the GBD 2019 and analyzed using a prevalence‐based approach. The per‐person direct expenditure and work loss days were from a multicenter study; the premature‐death‐related expenditure was estimated using a human capital approach. Projections were conducted in different simulated scenarios. All expenditure data were in Chinese Yuan (CNY) and discounted to 2019.

Results

In 2019, the estimated overall economic burden of CRC in China was CNY170.5 billion (0.189% of the local GDP). The direct expenditure was CNY106.4 billion (62.4% of the total economic burden), 91.4% of which was a direct medical expenditure. The indirect expenditure was CNY64.1 billion, of which 63.7% was related to premature death. The predicted burden would reach CNY560.0 billion in 2030 given constant trends for disease burden; however, it would be alternatively reduced to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsCost of IllnessHealth ExpendituresHumansChinaPrevalenceMaleFemaleMiddle AgedAgedAdultHealth Care Costs

Stichwörter der Autor:innen

Chinacolorectal cancercostseconomic burdenpopulation‐level

Autor:innen und Institutionen

  • Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Cancer Epidemiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
  • Department of Cancer Control and Prevention, Shenzhen Center for Chronic Disease Control, Shenzhen, China.
  • Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implement, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • The Daffodil Centre, The University of Sydney, a Joint Venture with Cancer Council New South Wales, Sydney, Australia.

ORCID-Profile: Hong Wang, Lin Lei, Wan-Qing Chen, Min Dai, Jie-Bin Lew, Ju-Fang Shi, Ni Li

Förderung

  • A Talent Incentive Plan Sponsored by Cancer Hospital, Chinese Academy of Medical Sciences
  • An Open Competition Grant from Health Policy and System Sciences of China Medical Board
  • National Natural Science Foundation of China
  • The Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences

Zitieren

APA

Wang, H., Li, Y. J., Lei, L., Liu, C. C., Chen, W. Q., Dai, M., Wang, X., Lew, J. B., Shi, J. F., Li, N., & He, J. (2024). Estimating the economic burden of colorectal cancer in China, 2019–2030: A population‐level prevalence‐based analysis. Cancer Medicine. https://doi.org/10.1002/cam4.6787

Vancouver

Wang H, Li YJ, Lei L, Liu CC, Chen WQ, Dai M, et al. Estimating the economic burden of colorectal cancer in China, 2019–2030: A population‐level prevalence‐based analysis. Cancer Medicine. 2024. doi:10.1002/cam4.6787

BibTeX
@article{Wang2024,
  author = {Wang, Hong and Li, Yan-Jie and Lei, Lin and Liu, Cheng-Cheng and Chen, Wan-Qing and Dai, Min and Wang, Xin and Lew, Jie-Bin and Shi, Ju-Fang and Li, Ni and He, Jie},
  title = {Estimating the economic burden of colorectal cancer in China, 2019–2030: A population‐level prevalence‐based analysis},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.6787}
}
Kostenlos starten →